Main Content
News - Ontario
Additional Insulin coverage for those living with Diabetes in Ontario
TORONTO, ONTARIO (December 3, 2008) – The Canadian Diabetes Association applauds the announcement made by the Government of Ontario for increasing access to insulin glargine for Ontarians living with diabetes. Insulin glargine, also known as Lantus has been added to the provincial drug formulary. It will provide an option for people with diabetes for whom other insulin treatments have not been effective in controlling blood glucose levels.
“This is a positive step in ensuring those with diabetes in Ontario have access to medication that helps them manage their condition,” said Gary O’Connor, Executive Director, Ontario, Canadian Diabetes Association. “We applaud the Government of Ontario for being committed to the area of diabetes management and providing coverage for alternative insulin therapy options.”
Insulin is a hormone produced by the pancreas to control the amount of glucose (sugar) in the blood. In people who have diabetes, the pancreas does not produce any or enough insulin, or is unable to effectively use the insulin it does produce. As a result, glucose builds up in the bloodstream, potentially leading to serious health problems such as blindness, heart disease, kidney problems, amputation, nerve damage and erectile dysfunction.
The Canadian Diabetes Association works in communities across the country to promote the health of Canadians and eliminate diabetes through our strong nationwide network of volunteers, employees, healthcare professionals, researchers, partners and supporters. In the struggle against this global epidemic, our expertise is recognized around the world. The Canadian Diabetes Association: setting the world standard. To learn more, visit diabetes.ca or call 1-800-BANTING (226-8464).
For more information, please contact:
Randi Garcha
Associate, Marketing & Communications
Canadian Diabetes Association
(416) 408-7207
 |
Support the Canadian Diabetes Association! |